

## Estimates of TB burden,<sup>a</sup> 2015

|                                    | Number (thousands)  | Rate (per 100 000 population) |
|------------------------------------|---------------------|-------------------------------|
| Mortality (excludes HIV+TB)        | 480 (380-590)       | 36 (29-45)                    |
| Mortality (HIV+TB only)            | 37 (21-57)          | 2.8 (1.6-4.3)                 |
| Incidence (includes HIV+TB)        | 2 840 (1 470-4 650) | 217 (112-355)                 |
| Incidence (HIV+TB only)            | 113 (58-186)        | 8.6 (4.4-14)                  |
| Incidence (MDR/RR-TB) <sup>b</sup> | 130 (88-180)        | 9.9 (6.7-14)                  |

## Estimated TB incidence by age and sex (thousands),<sup>a</sup> 2015

|         | 0-14 years    | > 14 years          | Total               |
|---------|---------------|---------------------|---------------------|
| Females | 136 (78-193)  | 860 (112-1 610)     | 995 (191-1 800)     |
| Males   | 119 (78-161)  | 1 730 (1 070-2 380) | 1 850 (1 150-2 540) |
| Total   | 255 (181-328) | 2 590 (1 750-3 420) | 2 840 (1 470-4 650) |

## TB case notifications, 2015

|  |           |
|--|-----------|
| Total cases notified                                   | 1 740 435 |
| Total new and relapse                                  | 1 667 136 |
| — % tested with rapid diagnostics at time of diagnosis |           |
| — % with known HIV status                              | 67%       |
| — % pulmonary  | 82%       |
| — % bacteriologically confirmed among pulmonary        | 64%       |

## Universal health coverage and social protection

|  |                  |
|--|------------------|
| TB treatment coverage (notified/estimated incidence), 2015             | 59% (36-110)     |
| TB patients facing catastrophic total costs                            |                  |
| TB case fatality ratio (estimated mortality/estimated incidence), 2015 | 0.20 (0.11-0.36) |

## TB/HIV care in new and relapse TB patients, 2015

|   | Number | (%) |
|---|--------|-----|
| Patients with known HIV-status who are HIV-positive | 44 652 | 4%  |
| — on antiretroviral therapy                         | 40 925 | 92% |

## Drug-resistant TB care, 2015

|   | New cases      | Previously treated cases         | Total number <sup>c</sup> |
|---|----------------|----------------------------------|---------------------------|
| Estimated MDR/RR-TB cases among notified pulmonary TB cases |                |                                  | 79 000 (72 000-87 000)    |
| Estimated % of TB cases with MDR/RR-TB                      | 2.5% (2.1-3.1) | 16% (14-18)                      |                           |
| % notified tested for rifampicin resistance                 | 6%             | 60%                              | 275 321                   |
| MDR/RR-TB cases tested for resistance to second-line drugs  |                |                                  | 8 976                     |
| Laboratory-confirmed cases                                  |                | MDR/RR-TB: 28 876, XDR-TB: 3 048 |                           |
| Patients started on treatment <sup>d</sup>                  |                | MDR/RR-TB: 26 966, XDR-TB: 2 130 |                           |

## Treatment success rate and cohort size

|   | Success | Cohort    |
|---|---------|-----------|
| New and relapse cases registered in 2014                        | 74%     | 1 609 547 |
| Previously treated cases, excluding relapse, registered in 2014 | 65%     | 74 368    |
| HIV-positive TB cases, all types, registered in 2014            | 76%     | 44 257    |
| MDR/RR-TB cases started on second-line treatment in 2013        | 46%     | 15 906    |
| XDR-TB cases started on second-line treatment in 2013           | 37%     | 248       |

## TB preventive treatment, 2015

|   |  |
|---|--|
| % of HIV-positive people (newly enrolled in care) on preventive treatment                                   |  |
| % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment |  |

## TB financing, 2016

|                                    |  |
|------------------------------------|--|
| National TB budget (US\$ millions) | 280  |
| Funding source                     | 38% domestic, 62% international, 0% unfunded |

Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation with countries. Estimates are rounded and totals are computed prior to rounding.

<sup>a</sup> Ranges represent uncertainty intervals. Estimates of TB incidence and mortality are interim in nature, pending results from the national TB prevalence survey planned for 2017/2018.

<sup>b</sup> MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.

<sup>c</sup> Includes cases with unknown previous TB treatment history.

<sup>d</sup> Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed.

